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ABSTRACT: Structural variants of R-galactosylceramide
(RGC) that activate invariant natural killer T cells (iNKT
cells) are being developed as potential immunomodulatory
agents for a variety of applications. Identiﬁcation of speciﬁc
forms of these glycolipids that bias responses to favor produc-
tion of proinﬂammatory vs anti-inﬂammatory cytokines is
central to current eﬀorts, but this goal has been hampered by
the lack of in vitro screening assays that reliably predict the
in vivo biological activity of these compounds. Here we
describe a ﬂuorescence-based assay to identify functionally
distinct RGC analogues. Our assay isbased on recent ﬁndings
showing that presentation of glycolipid antigens by CD1d
molecules localized to plasma membrane detergent-resistant
microdomains (lipid rafts) is correlated with induction of
interferon-γ secretion and Th1-biased cytokine responses.
Using an assay that measures lipid raft residency of CD1d
molecules loaded with RGC, we screened a library of ∼200
synthetic RGC analogues and identiﬁed 19 agonists with
potential Th1-biasing activity. Analysis of a subset of these
novel candidate Th1 type agonists in vivo in mice conﬁrmed
their ability to induce systemic cytokine responses consistent
withaTh1typebias.Theseresultsdemonstratethepredictive
value of this novel in vitro assay for assessing the in vivo
functionality of glycolipid agonists and provide the basis for a
relatively simple high-throughput assay for identiﬁcation and
functional classiﬁcation of iNKT cell activating glycolipids.
I
nvariant natural killer T cells (iNKT cells) constitute a unique
lymphocyte subset that participates in immune responses
against a wide variety of infectious diseases and tumors and also
plays a role in regulating allergic and autoimmune diseases.
1,2
These cells express surface markers associated with both con-
ventional thymus-derived (T) cells and natural killer (NK) cells.
Theyalsoexpress an invariant R chain as a component of their T
cell antigen receptors (TCRs).
1 The TCRs of these cells are
speciﬁc for a range of diﬀerent glycolipid antigens, which are
recognized as noncovalent complexes with CD1d, a cell surface
glycoprotein that is homologous to class I antigen presenting
molecules encoded by the major histocompatibility complex
(MHC).
3Theprototypeglycolipidantigenofmouseandhuman
iNKT cells is a form of R-galactosylceramide (RGC) designated
as KRN7000 (1).
4 Recognition of this glycolipid is highly
conserved between mouse and human, although studies suggest
subtle diﬀerences in responses by iNKT cells in these species.
5
The capability of iNKT cells to activate or regulate NK cells,
dendritic cells (DCs), neutrophils, macrophages, and B and
conventional T cells makes them an attractive target for immu-
notherapeutics. Indeed, activation of iNKT cells with KRN7000
has been shown to augment beneﬁcial host immunity in some
models and to suppress autoimmune diseases in others.
2,6
Administration of 1 to miceinduces a mixed cytokineresponse
that is characterized by secretion of both IFNγ and IL-4, the
prototypical cytokines deﬁning anti-inﬂammatory (Th2) versus
proinﬂammatory (Th1) cellular immune responses.
7 The agonist
1 is therefore classiﬁed as inducing a nonpolarized or Th0
response. The secretion of IL-4 peaks at 2 h post-injection, while
IFNγsecretionpeaksat∼12handissustainedforupto36hafter
glycolipid administration. The majority of this systemic IFNγ
secretiondoesnotoriginatefromtheiNKTcellsbutistheresultof
secondaryactivationofNKcells.
8VariantsofRGCwithtruncated
or unsaturated acyl chains (e.g., RGC C20:2; compound 2 in
Figure 1) can bias the response to favor production of Th2-type
cytokines.
3,8 10ThisischaracterizedbystrongIL-4secretionwith
reduced IFNγ production due to the failure to transactivate NK
cells.SuchTh2-biased iNKTcellactivatorshave been found to be
superior for treatment in several mouse models of autoimmune
disease.
7,10Onthecontrary,iNKTcellagoniststhatbiasresponses
to stronger and more sustained production of Th1-type cytokines
are more eﬀective as adjuvants for inducing protective immunity
against infections and for anticancer immunity. The most exten-
sivelystudiedTh1-biasingagonististheC-glycosideofKRN7000,
R-C-GC (3),inwhichtheoxygenof theglycosidic bondhasbeen
replaced with a one-carbon linker.
3,11 This agonist induces
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minimalsecretionofIL-4andisassociatedwithenhancedNKcell
activation that results in higher and more sustained IFNγ secre-
tion. Variants of this agonist containing an oleﬁn linkage also
display enhanced Th1 bias in cytokine responses.
12
A commonly used screening assay to identify new RGC
analogues is based on the culture of splenic cells in the presence
of candidate agonists followed by quantiﬁcation of cytokines in
thesupernatantsandcalculationoftheratioofIL-4toIFNγ.
8,10,13
Many Th2-biasing iNKT agonists have been successfully identi-
ﬁed in this way. Unfortunately, this type of screening assay has
proved to be less eﬀective for identifying Th1-biasing agonists.
Generally, the prototypical Th1-biasing R-C-GC analogue 3 has
been found to display little or no activity in such cell culture
assays, despite the Th1-biased response that is observed in vivo
followinginjectionintomice.
14Atpresent,identiﬁcationofstrong
IFNγ-inducing or Th1-biasing agonists is possible only by
analyzingresponsesofintactanimalsfollowingsystemicinjection
of candidate agonists, an approach that is not amenable to high-
throughput screening. This represents a major limitation in the
identiﬁcation of additional and potentially more potent IFNγ-
inducingiNKTcellagonists.Thus,thedevelopmentofarelatively
simpleandrapidinvitroassaythatreliablypredictstheTh1versus
Th2functionalitywouldbeanimportantsteptowardaccelerating
thedevelopmentofnewandmoreeﬀectiveiNKTcellagonistsfor
a wide variety of potential clinical applications.
We recently showed that RGC agonists that induce strong
IFNγ secretion from NK cells have diﬀerences in CD1d loading
and presentation relative to Th2-biasing agonists.
13 The former
agonists load CD1d in an endocytic compartment and are
selectively traﬃcked to lipid raft microdomains in the plasma
membrane. In contrast, Th2-biasing agonists are loaded directly
into CD1d proteins present on the cell surface. Initial studies
indicated that CD1d complexes formed with Th2-biasing ago-
nists tend to be pH-labile and therefore dissociate at the low pH
typicalofendosomalcompartments.Sinceendosomaltraﬃcking
is required for lipid raft localization, these complexes are
excluded from lipid rafts (Figure 1). Localization in lipid rafts
is probably responsible for optimal stimulation of iNKT cells,
which ensures that transactivation of NK cells takes place. We
therefore evaluated the possibility of using quantitation of lipid
raft residency of CD1d/glycolipid complexes as a method of
identifying new RGC agonists that have the potential to stimu-
latestrongIFNγproductionandTh1-biasedcytokineresponses.
Here we describe the development of a rapid two-step ﬂow
cytometry-based assay employing this principle to identify
potent RGC analogues and predict their functional properties.
To screen a large library of RGC analogues, we ﬁrst selected
RGC candidate agonists that showed eﬃcient binding and
presentation by CD1d. Individual glycolipids were incubated at
100nMfor12hwiththeCD1d
þmurinedendriticcelllineJAWS
II
15 followed by quantitation of the binding of monoclonal
antibody (mAb) L363 to cell surface CD1d/glycolipid com-
plexes by ﬂow cytometry. This mAb is speciﬁc for complexes
formed by the binding of RGC to murine CD1d.
16 Using this
approach, we screened a library of 193 synthetic RGC analogues
containingmodiﬁcationsoffattyacyl,sphingosine,andglycosidic
linkages. This library, provided in Table S1 in the Supporting
Information (SI), included a large diversity of fatty acyl mod-
iﬁcations as well as all eight stereoisomers of KRN7000 and
carbasugarreplacementofthegalactoseresidues.Severalofthese
agonists have been tested in vitro and in vivo for their iNKT
stimulatory activities (Table S2). In the initial stage of screening,
we selected all of the agonists that gave an increase in L363
staining of at least 4 standard deviations above the median
ﬂuorescence intensity (MFI) of untreated control cells
(Figures S1 and S2 in the SI). This represented a relatively
stringentcriterion forCD1d bindingthatactuallyexcludedsome
of the known weak iNKT cell agonists (e.g., the weak Th2-
biasing compound known as OCH).
7 This selection reduced the
candidate agonists to 71, which were then investigated for lipid
raft localization using the detergent extraction method.
For quantitation of the extent of lipid raft residency, we
exploited the fact that lipid raft microdomains are resistant to
extraction with nonionic detergents such as Triton X-100 (Tx-
100). Thus, JAWS II cells were incubated with each RGC
analogue at 100 nM concentration and stained with Alexa Fluor
647-conjugated mAb L363. Since plasma membrane lipid rafts
are detergent-resistant, CD1d/glycolipid agonist complexes
localized in lipid rafts cannot be extracted, and a minimal
decrease in ﬂuorescence intensity is observed over time. In
contrast, for the CD1d/glycolipid agonist complexes that are
excluded from lipid rafts, the MFI decreases sharply following
Tx-100 addition. We also considered that a decrease in MFI
following Tx-100 treatment could be caused by the dislodge-
ment of ﬂuorescently conjugated mAb from the CD1d/RGC
complexes. This possibility was excluded by studies of the eﬀect
of Tx-100 concentration on the binding of L363 with its ligand,
asweshowedusingacell-freeassaythatthelowconcentrationof
Tx-100 (0.06%) used for this assay did not cause dissociation of
L363 mAb from CD1d/RGC complexes (Figure S3). To per-
form the analysis of Tx-100 stability of cell surface CD1d/RGC
complexes, the MFI of cellswas ﬁrstrecordedfor∼5 s to obtain
a baseline starting value, and then Tx-100 was added to a ﬁnal
concentration of 0.06%. The sample was vortexed brieﬂyt o
ensure uniform mixing, and data were acquired using ﬂow
cytometry in kinetic mode to visualize changes in MFI over
time (Figure 2A). To validate the screening assay, we chose
agonists 1 3 as representative Th0, Th2, and Th1 cytokine-
biasing glycolipid agonists. CD1d complexes containing agonist
2wererapidlyeluted from thecellsurface by Tx-100(Figure2),
consistent with their exclusion from lipid rafts. This agonist
inducedhighlevelsofIL-4butfailedtoinducesustainedIFNγat
the 24 h time point. In contrast, both 1 and 3 were presented by
detergent-resistant,lipid-raft-residentCD1dandinducedstrong
IFNγ responses in mice with 1 3 orders of magnitude greater
T h 1b i a st h a nf o r2.
Since several known Th2-biasing RGC analogues in the
library showed reductions of up to 70% or more in the initial
ﬂuorescence during a 30 s exposure to Tx-100, we classiﬁed
agonists as negative for lipid raft localization if they showed
Figure 1. Prototype RGC activators of iNKT cells and a schematic
summarizingpathwaysfortheirloadingontoandpresentationbyCD1d.5200 dx.doi.org/10.1021/ja200070u |J. Am. Chem. Soc. 2011, 133, 5198–5201
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more than 50% reduction in MFI within 30 s after addition of
Tx100. Out of the 71 compounds analyzed, 51 were rapidly
extracted with Tx100, consistent with their being bound pre-
dominantly to CD1d proteins localized outside of lipid rafts
(Figure S4A,B). Of these 51 agonists, four had been previously
studied for biological activity in vivo by injection into mice,
7,10
In all cases Th2-biased serum cytokine responses were elicited
with high secretion of IL-4 relative to IFNγ (Table S2). These
ﬁndings were consistent with the predictions of our lipid raft
presentation model and indicated that our assay was able to
accurately identify Th2-type iNKT cell agonists. In addition, we
identiﬁed 17 new agonists in our library that formed CD1d
complexes that were resistant to extraction with detergent
(Figure 3 and Figures S4C and S5) and were thus predicted
to induce strong and sustained IFNγ secretion following
glycolipid administration in vivo.
To test this prediction, we chose a random sample of seven
agonists (5, 6, 8, 9, 10, 12, and 16) from this group and tested
their activities in vivo by injecting them individually into mice
(4nmolpermouse)(Figure4).OneofthepredictednovelTh2-
biasing agonists (4) was included as a reference standard. 4
induced relatively low IFNγ at the 2 h time point, and this was
undetectable by the 24 h time point. In contrast, all seven
compounds that were presented by non-Tx-100-extractable
CD1d molecules induced signiﬁcantly higher levels of IFNγ
(Figure 4A) and sustained measurable serum levels of this
cytokine for extended time periods of up to 36 h (Figure S6).
A useful indicator of Th1 bias in the cytokine response is the
ratioofIFNγobserved24hafterglycolipidinjectiontothatfor
peakIL-4secretionat2h.Thisratiohastypicallybeenfoundto
be 0.1 0.2 for well-characterized Th2-biasing agonists such as
2 (Figure 2D). In contrast, the prototypical agonist 1 gives a
ratio of ∼1, while the strongly Th1-biasing agonist 3 induces
very high IFNγ with very low IL-4 secretion, resulting in
∼2 fold increase in this ratio (Figure 2D). The 4-dehydroxy-
sphingoid base variant of 2 (agonist 5) behaved like a strongly
Th1-biasing agonist in vivo in mice, showing the highest
secretion of IFNγ at 24 h with minimal IL-4 induction relative
to all of the other agonists tested (Figure 4B).
Our data also showed that the extent of localization of CD1d/
RGC complexes into lipid rafts was directly related to the fatty
acylchainlengthoftheglycolipid.Thiswasreadilyapparentfrom
a comparison of the extents of lipid raft localization for six
diﬀerent agonists from our library that diﬀered only in their fatty
acyl chain lengths (Figure 5A). All of the agonists containing
saturated fatty acyl moieties with < 16 carbons were excluded
from lipid rafts, whereas all of the agonists containing saturated
acylchainswith16 26carbonsshowedenhancedlocalizationin
lipid rafts. Introduction of diunsaturation in the C20 acyl chain
abolished lipid raft localization of CD1d-loaded complexes for
agonist 2, suggesting that the hydrophobicity of the acyl chain
rather than simplythe chain length is the feature that determines
the extent of traﬃcking and localization of CD1d/RGC com-
plexes to lipid rafts. Further increasing the hydrophobicity of 1
byreplacingtheglycosidiclinkagewithCH2(asinthecaseof3),
replacing the carbonyl oxygen with a sulfur atom (agonist 12),
creatingdeoxyversions(agonists5,6,9,and10),orreplacingthe
galactosesugarwithastructurallyanalogouscarbasugar(agonists
9 11)didnotsigniﬁcantlyincreaselipidraftlocalizationrelative
to 1 (Figure 5B). Furthermore, the carbasugar variant of 2 was
still lipid-raft-excluded and showed a Th2-biased cytokine re-
sponse in vivo (data not shown). Importantly, the screening
assaydescribedhereistoourknowledgetheonlyonetodatethat
has been demonstrated to correctly predict the Th1-biasing
ability of 3 using an in vitro method. However, given the similar
levels of raft localization for all Th1/Th0-biasing glycolipids, the
very pronounced IFNγ responses and Th1 biases of compounds
3 and 5 cannot be explained solely by enhanced lipid raft
association. The other factors that further augment the Th1 bias
for these compounds remain to be established.
Figure 2. Validation of the rapid in vitro ﬂuorescent antibody staining
assay to predict the functional activity of RGC analogues. (A) Plot of
detergent extraction from JAWS II dendritic cells of CD1d/glycolipid
complexes formed with known Th1- and Th2-biasing RGC agonists (i.
e., compounds 1 3 in Figure 1). (B) In vivo serum IFNγ levels at
various time points following administration of 4 nmol of RGC
analogues. (C) Serum IL-4 secretion measured 2 h after injection of
RGC analogues. (D) Ratio of the IFNγ level observed at 24 h with that
of peak IL-4 secretion 2 h after glycolipid administration.
Figure 3. Structures of predicted cytokine-biasing agonists. 4 was
presented by Tx-100-extractable CD1d molecules and thus predicted
to be a Th2-biasing agonist. In contrast, agonists 5 21 were presented
by detergent-resistant (i.e., raft-localized) CD1d and were therefore
identiﬁed as potential strong IFNγ inducers and Th1-biasing agonists.5201 dx.doi.org/10.1021/ja200070u |J. Am. Chem. Soc. 2011, 133, 5198–5201
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In summary, we have described a n e wi nv i t r om e t h o df o rr a p i d
screeningoflargelibrariesofRGCanaloguestopredicttheirinvivo
functionality. Our technique is simple and robust, and its use can
substantially reduce the time and materials required for initial
characterization of biological activity. The use of this straightfor-
wardinvitroapproachshouldfurtheradvanceourunderstandingof
structure activity relationships for RGC analogues and thus
facilitate the discovery of iNKT cell agonists for a wide variety of
immunotherapeutic applications. Our ﬁndings also provide further
support for the importance of lipid raft localization of CD1d/RGC
complexes as one of the signiﬁcant factors that tunes the iNKTcell
response. Further studies are underway to explore whether the
approach described here can be applied to predict functional
responses induced by glycolipid antigens in humans.
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Figure 4. In vivo serum cytokine responses of selected RGC agonists.
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agonists 2 and 4. The value for 2 was compared with the values for
the other agonists using one-way ANOVA with Dunnet correction.